Hard to value AC8 at this stage. With 216M SOI, the MC is...

Hard to value AC8 at this stage.

With 216M SOI, the MC is approaching $200M. No revenue yet and Directors yet to make a determination of fair vaule of the AusCann assets.

$4.8M cash on hand. Projected Q1 outflows $1.274M. Another CR possible to fund company activities until cash-flow positive.

First harvest in Chile on track for April 2017 for clinical trials. Depending on results, may lead to commercial sales.


A lot of speccies seem to top out around $200M MC with no revenue.

I like the prospects here and will be watching AC8 with keen interest over the coming months.